CytomX stock plunges to 52-week low, touches $0.6

CytomX Therapeutics Inc (NASDAQ:CTMX). shares have tumbled to a 52-week low, with the stock price hitting just $0.6, marking a stark contrast to its performance over the past year. According to InvestingPro data, the company maintains a healthy balance sheet with more cash than debt, while trading at a modest P/E ratio of 3.67 and showing strong revenue growth of 33.66% in the last twelve months. The biopharmaceutical company, which specializes in developing cancer treatments, has seen its shares plummet, reflecting a significant 1-year change with a decline of -76.17%. Investors are closely monitoring the company’s progress and potential catalysts that could influence its stock valuation, as it navigates through a challenging period marked by this new low. InvestingPro analysis indicates the stock is currently in oversold territory, with additional insights available through the comprehensive Pro Research Report, which covers what really matters for over 1,400 US stocks.

In other recent news, CytomX Therapeutics has announced a significant restructuring plan aimed at extending its cash runway into the second quarter of 2026. This plan includes a 40% reduction in workforce, primarily affecting general and administrative roles, as well as early research positions. The restructuring is expected to incur costs of approximately $5 million to $6 million, primarily for severance and related expenses. CytomX has $117.6 million in cash and cash equivalents as of the end of the third quarter of 2024, and the restructuring is part of a strategy to prioritize its lead drug candidate, CX-2051, which targets metastatic colorectal cancer. The company plans to release Phase 1 data for CX-2051 in the first half of 2025. In other developments, CytomX faces a potential Nasdaq delisting due to its stock price falling below the minimum required bid price, but it has until August 25, 2025, to regain compliance. Analyst firm H.C. Wainwright has maintained a Neutral rating on CytomX, awaiting meaningful clinical data before reassessing its stance. Despite these challenges, CytomX continues its research collaborations with major pharmaceutical companies, including Amgen (NASDAQ:AMGN) and Bristol-Myers Squibb (NYSE:BMY).

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.